...
首页> 外文期刊>Cancer Management and Research >Preoperative circulating FPR and CCF score are promising biomarkers for predicting clinical outcome of stage II–III colorectal cancer patients
【24h】

Preoperative circulating FPR and CCF score are promising biomarkers for predicting clinical outcome of stage II–III colorectal cancer patients

机译:术前循环FPR和CCF评分是有前途的生物标志物,用于预测II-III阶段结直肠癌患者的临床结果

获取原文
           

摘要

Introduction: Inflammation and nutrition are considered as two important causes leading to the progression and poor survival of colorectal cancer (CRC). The objective of this study is to investigate the prognostic significance of preoperative albumin-to-fibrinogen ratio (AFR), fibrinogen-to-pre-albumin ratio (FPR), fibrinogen (Fib), albumin (Alb), and pre-albumin (pre-Alb) in CRC individuals. Materials and methods: In this study, 3 years’ follow-up was carried out in 702 stage I–III resected CRC patients diagnosed between January 2008 and December 2013. The optimal cutoff points and prognostic values of AFR, FPR, Fib, Alb, pre-Alb, and a novel carcinoembryonic antigen (CEA)-carbohydrate antigen 19-9 (CA199)-FPR (CCF) score were assessed by X-tile software, Kaplan–Meier curve, and Cox regression model. We established the CRC prognostic nomogram, and its predictive efficacy was determined by Harrell’s concordance index (c-index). Results: Our results showed that high FPR was obviously correlated with poor survival of CRC patients. The prognostic predictive efficacy of CCF score was superior to FPR, CEA, CA199, CEA-CA199 (CCI), and CEA-FPR (CFI) score. Moreover, stage II–III patients harboring high FPR or elevated CCF (score≥1) could benefit from adjuvant chemotherapy, rather than those with low FPR or CCF (score=0). Additionally, the c-index (0.728) of the nomogram containing CCF score was significantly higher than that (0.626) without it ( p 0.01). Conclusion: These findings illustrated that FPR and CCF score were promising biomarkers to predict the prognosis of CRC and to classify the stage II–III patients who could benefit from the adjuvant chemotherapy.
机译:介绍:炎症和营养被认为是导致直肠癌(CRC)的进展和差的进展的重要原因。本研究的目的是探讨术前白蛋白 - 纤维蛋白原比(AFR),纤维蛋白原对蛋白酶比(FPR),纤维蛋白原(FIB),白蛋白(ALB)和预白蛋白(在CRC个人中的预溴化。材料和方法:在本研究中,在2008年1月至2013年1月至12月诊断的702阶段切除的CRC患者中进行了3年的后续行动。AFR,FPR,FIB,ALB的最佳截止点和预后价值,通过X-Tile软件,Kaplan-Meier曲线和Cox回归模型评估预溴化癌和新型癌胚抗原(CEA)-Carbo水合物抗原19-9(CA199)-FPR(CCF)评分。我们建立了CRC预后载体图表,其预测疗效由Harrell的一致性指数(C-Index)决定。结果:我们的研究结果表明,HIGH FPR明显与CRC患者的差的存活率相关。 CCF评分的预测预测疗效优于FPR,CEA,CA199,CEA-CA199(CCI)和CEA-FPR(CFI)得分。此外,II-III阶段患者患有高FPR或升高的CCF(得分≥1)可以从佐剂化疗中受益,而不是低FPR或CCF(得分= 0)。另外,含有CCF得分的墨迹图的C折射率(0.728)显着高于其(0.626)(P <0.01)。结论:这些研究结果表明,FPR和CCF评分是有前途的生物标志物,以预测CRC的预后,并分类可从佐剂化疗中受益的II-III患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号